Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROR1 CAR-T in advanced ROR1+ malignancies
NCT02706392Phase 1Terminated
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Mar 2016
- Primary completion
- May 2021
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ROR1 CAR-T cells in chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), acute lymphoblastic leukemia (ALL) and 2 more, sponsored by Fred Hutchinson Cancer Center. Primary endpoint: Number of Participants That Experienced Adverse Events. Started Mar 2016; status: terminated.
02
Drugs
ROR1 CAR-T cells
03
Conditions
chronic lymphocytic leukemia (CLL)mantle cell lymphoma (MCL)acute lymphoblastic leukemia (ALL)non-small cell lung cancer (NSCLC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02706392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02706392.